Tadalafil vs Sildenafil: Half-Life, Onset, Side Effects (2026 Comparison)

Quick answer

Tadalafil and sildenafil are both PDE5 inhibitors and share the same molecular target. The clinically meaningful differences reduce to four parameters: half-life (tadalafil 17.5 h, sildenafil 4 h, the dominant distinction), onset (sildenafil faster at 30 to 60 minutes vs tadalafil at 1 to 2 hours), food sensitivity (sildenafil reduced by high-fat meal, tadalafil unaffected), and selectivity profile (sildenafil has PDE6 cross-affinity producing visual artifacts, tadalafil has PDE11 cross-affinity producing back pain). Both share the absolute contraindication of concurrent organic nitrate use. The choice between them depends on whether daily-dose pattern, weekend coverage, and food-independent absorption (tadalafil) outweigh faster onset and shorter washout window (sildenafil).

Table of contents

1. Side-by-side comparison table
2. Pharmacokinetics: 17.5h vs 4h
3. Onset and food sensitivity
4. Dosing patterns
5. Side-effect profiles
6. Cost considerations (research compound)
7. When each is preferred
8. Frequently asked questions
9. References

---

Side-by-side comparison table

Property	Tadalafil	Sildenafil
Brand name (originator)	Cialis	Viagra
Mechanism	PDE5 inhibitor	PDE5 inhibitor
Selectivity	PDE5 >> PDE6, partial PDE11 cross-affinity	PDE5 ≈ PDE6
IC50 at PDE5 (radioimmunoassay)	~2.35 nM	~5.22 nM
Elimination half-life	~17.5 hours	~4 hours
T_max	~2 hours	~1 hour
Effective window	up to 36 hours	up to 4 to 6 hours
Food effect	None	Reduces absorption ~30% with high-fat meal
Daily-dose pattern	2.5 or 5 mg approved	Not practical (short half-life)
On-demand pattern	10 or 20 mg	25, 50, or 100 mg
Distinctive side effect	Back pain (PDE11 cross-affinity)	Vision changes (PDE6 cross-affinity)
Headache rate	10 to 15%	10 to 15%
Flushing rate	3 to 5%	5 to 10%
BPH/LUTS approval	Yes (5 mg daily)	No
Pulmonary hypertension brand	Adcirca	Revatio
Nitrate washout window	48 hours	24 hours

According to PubMed, the comparative IC50 measurements above were determined by radioimmunoassay against human recombinant PDE isozymes; both drugs are potent PDE5 inhibitors in the low nanomolar range (Wang et al., 2013, PMID 23937247, DOI).

Pharmacokinetics: 17.5h vs 4h

The 4-fold difference in elimination half-life is the single feature that drives nearly every practical distinction between tadalafil and sildenafil.

According to PubMed-indexed pharmacokinetic data, tadalafil’s apparent elimination half-life in healthy adults is approximately 17.5 hours, while sildenafil’s is approximately 4 hours. After a single oral dose of tadalafil, plasma concentrations remain above the threshold for clinically meaningful PDE5 inhibition for approximately 36 hours. After a single oral sildenafil dose, the corresponding window is approximately 4 to 6 hours (Porst et al., 2009, PMID 19756466, DOI; Corbin and Francis, 2002, PMID 12166544).

This translates to three operational differences:

Steady-state. Tadalafil reaches steady-state plasma concentration at approximately day 5 of daily dosing (7 elimination half-lives, the standard pharmacokinetic rule of thumb). Sildenafil cannot practically reach steady-state with daily dosing because the half-life is shorter than the dosing interval; achieving meaningful plasma concentration with a daily-dose pattern would require 4 to 6 doses per day. Daily-dose protocols are therefore practical for tadalafil and not for sildenafil.

Washout. Tadalafil’s full clearance from plasma after the last dose requires approximately 3 to 4 days. Sildenafil’s full clearance requires approximately 24 hours. This matters most for emergency contexts: if a patient on a PDE5 inhibitor experiences an acute coronary event and requires emergency nitrate administration, the relevant washout window is 48 hours for tadalafil but only 24 hours for sildenafil. The longer tadalafil washout window means closer hemodynamic monitoring is required if nitrates must be given within that interval.

Accumulation. Daily 5 mg tadalafil produces a steady-state plasma trough approximately 1.6-fold higher than the trough after a single 5 mg dose, because the next dose lands before the previous one is fully eliminated. Sildenafil accumulates negligibly in any clinically used dosing pattern.

The pharmacokinetic difference is the engineering reason for tadalafil’s daily-dose label and the BPH/LUTS indication.

Onset and food sensitivity

Onset. Sildenafil’s onset is approximately 30 to 60 minutes after oral administration. Tadalafil’s is approximately 1 to 2 hours. The 30-to-60-minute difference matters in research designs that require precise time-to-effect characterization.

For an on-demand dosing pattern where the user has predictable 30-minute pre-activity timing, sildenafil’s faster onset is the cleaner fit. For a use case where the activity timing is uncertain or extended, tadalafil’s slower onset is offset by the much longer effective window.

Food. Sildenafil’s absorption is reduced by approximately 30 percent in peak plasma concentration and 11 percent in AUC when co-administered with a high-fat meal. Practically, this requires sildenafil to be taken on an empty stomach (or with a low-fat meal) for predictable pharmacokinetics. Tadalafil’s absorption is not meaningfully altered by food, including high-fat meals (Corbin and Francis, 2002, PMID 12166544).

The food-effect difference is the operational reason daily-dose tadalafil protocols are practical: a researcher does not need to coordinate the dose with fasting windows. For sildenafil, daily dosing would require both a 4-times-daily schedule (to maintain plasma concentration) and consistent fasted-stomach timing for each dose, which is operationally infeasible.

Dosing patterns

Tadalafil supports two patterns: daily-dose at 2.5 or 5 mg, or on-demand at 10 or 20 mg. Both have published evidence bases and regulatory approvals. The daily-dose pattern is approved for ED, BPH/LUTS, and combined ED/BPH; the on-demand pattern is approved for ED.

Sildenafil supports one pattern: on-demand at 25, 50, or 100 mg. Daily-dose sildenafil is not regulatory approved at any dose for ED, and the short half-life makes the daily-dose pattern operationally impractical.

For research protocols requiring continuous PDE5 inhibition (BPH/LUTS research, endothelial function research, post-prostatectomy penile rehabilitation context), tadalafil is the appropriate choice. For research protocols requiring discrete on-demand peak-effect exposure, either drug works, with the trade-offs above.

The “weekend pill” framing for tadalafil 20 mg derives from the 36-hour window: a single Friday-evening dose covers Saturday and most of Sunday without re-dosing. The same coverage with sildenafil 100 mg would require 6 to 9 redoses across the same window.

Side-effect profiles

The headline rates of common adverse events are similar between tadalafil and sildenafil. Both produce headache (10 to 15 percent), flushing (3 to 10 percent), dyspepsia (2 to 4 percent), and nasal congestion (1 to 3 percent) at approximately overlapping incidences.

The distinguishing axis is the cross-reactivity-driven side effects, which differ in molecular mechanism and clinical pattern.

Sildenafil and PDE6: vision-related side effects. Sildenafil has measurable PDE5/PDE6 cross-affinity. PDE6 is enriched in retinal photoreceptor outer segments and participates in phototransduction. Inhibition of PDE6 produces transient visual artifacts including blue-tinged vision, impaired blue-yellow discrimination, and increased light sensitivity. Reported incidence is approximately 1 to 3 percent. The effects are dose-dependent, peak with peak plasma concentration at approximately 60 minutes post-dose, and resolve within 4 to 6 hours along with the elimination half-life. According to PubMed, this PDE6 cross-affinity is an established class signal that distinguishes sildenafil from the more PDE5-selective inhibitors (Kayık et al., 2017, PMID 28150511, DOI).

Tadalafil and PDE11: back pain and myalgia. Tadalafil has measurable PDE5/PDE11 cross-affinity. PDE11 is expressed in skeletal muscle, prostate, testis, salivary gland, and pituitary tissue. PDE11 inhibition is the leading molecular hypothesis for the tadalafil-specific back pain and myalgia pattern. Reported incidence is approximately 3 to 7 percent (dose-dependent: 3 percent at 10 mg, 7 percent at 20 mg). The pattern develops 12 to 24 hours after dosing, lasts 12 to 48 hours, and tends to attenuate with continued dosing.

The two side-effect signatures are largely non-overlapping. Sildenafil users rarely report back pain at the rate tadalafil users do; tadalafil users rarely report visual artifacts at the rate sildenafil users do. For a researcher choosing between the two drugs based on prior PDE5 inhibitor experience, the side-effect profile they have already encountered (or want to avoid) can be the deciding factor.

Cardiovascular and other class effects. Both drugs share the absolute contraindication with organic nitrates and riociguat, the relative interaction with alpha-blockers and antihypertensives, and the rare but serious class effects of NAION (non-arteritic anterior ischemic optic neuropathy), sudden sensorineural hearing loss, and priapism. None of these distinguish between the two drugs.

According to PubMed, comparative reviews of the PDE5 inhibitor class have concluded that overall efficacy and safety profiles are similar across sildenafil, tadalafil, and vardenafil, with the differences concentrated in pharmacokinetics and the cross-reactivity-driven side-effect signatures discussed here (Carson 2006, PMID 16526979).

Cost considerations (research compound)

Both tadalafil and sildenafil have been off-patent for several years in most jurisdictions, and generic versions of both are widely available. At the research-compound level, per-dose costs depend on pack size, dose strength, and supplier markup; both drugs are priced in similar ranges.

A practical observation: tadalafil’s 36-hour window means a single 20 mg dose covers approximately 7-fold more activity time than a single 100 mg sildenafil dose’s 6-hour window. On a per-active-window basis, tadalafil is therefore cheaper than sildenafil when both are priced at similar per-tablet rates. This is one of the practical reasons the daily-dose tadalafil pattern is cost-competitive even at the steady-state requirement of 30 doses per month.

Elite Bio Supply currently distributes tadalafil 20 mg only. Sildenafil is not in our catalog at the time of this writing. For research projects that require sildenafil specifically, sourcing through other channels is the appropriate path.

When each is preferred

Tadalafil is preferred when:

• The research design requires continuous PDE5 inhibition (BPH/LUTS, endothelial function, post-prostatectomy penile rehabilitation, combined ED+BPH research).
• The activity timing is uncertain or extended over multi-day windows.
• Food schedule is unpredictable and the researcher cannot reliably administer doses on an empty stomach.
• A prior trial of sildenafil produced bothersome visual side effects.
• The published literature for the specific question being asked is denser for tadalafil (BPH/LUTS, daily-dose RCTs, post-prostatectomy rehabilitation).

Sildenafil is preferred when:

• The research design requires discrete on-demand peak-effect exposure with precise time-to-effect characterization.
• The fastest onset is operationally important.
• A prior trial of tadalafil produced bothersome back pain or myalgia.
• The shorter washout window is operationally relevant (e.g., a research design in which a researcher might require nitrates within 48 hours of the most recent dose).

According to PubMed, preference trials comparing tadalafil and sildenafil in the same patients have generally favored tadalafil, with the longer duration of action being the most commonly cited reason. However, the same review notes that preference-trial methodology has limitations, and real-world prescription-filling and sales data have not always reflected the preference-trial results, suggesting that emotional, social, and use-case-specific factors interact with the pharmacological profile in ways that simple preference data does not capture (Giannitsas et al., 2008, PMID 19920956).

The bottom line for research design: choose the drug whose pharmacokinetic and side-effect profile fits the question being asked. Both are effective PDE5 inhibitors with similar safety profiles in pivotal trials. The tradeoffs above are real but neither drug is generically superior.

Frequently asked questions

Which has a longer half-life?
Tadalafil at 17.5 hours, vs sildenafil at 4 hours. This 4-fold difference is the most clinically meaningful distinction between the two drugs and drives most other practical differences (dosing patterns, washout time, food effect).

Which acts faster?
Sildenafil onset is typically 30 to 60 minutes; tadalafil onset is 1 to 2 hours. Sildenafil’s faster onset is offset by its much shorter window of efficacy.

Which is more affected by food?
Sildenafil. A high-fat meal reduces absorption rate and peak concentration by approximately 30 percent. Tadalafil absorption is not meaningfully affected by food, which is why it is preferred for daily-dose protocols.

Is the side-effect profile different?
Yes, distinctively. Sildenafil’s PDE6 cross-affinity produces visual side effects (blue tint, light sensitivity) in 1 to 3 percent of users. Uncommon with tadalafil. Tadalafil’s PDE11 cross-affinity produces back pain and myalgia (3 to 7 percent). Uncommon with sildenafil. Headache and flushing rates are similar.

Which is preferred for daily dosing?
Tadalafil. Its 17.5-hour half-life and food-independent absorption support practical daily dosing at 2.5 or 5 mg. Sildenafil’s short half-life makes daily-dose protocols impractical (would require 4 to 6 doses per day for steady-state).

Which is preferred for spontaneity?
Tadalafil’s 36-hour window covers a full weekend from a single dose. Sildenafil’s 4-hour effective window requires more deliberate timing.

Are the contraindications the same?
Yes. Both are absolutely contraindicated with organic nitrates and riociguat. Both have similar relative contraindications around severe cardiovascular disease, severe hepatic/renal impairment, and concurrent strong CYP3A4 inhibitors.

References

References sourced via PubMed.

---

Research use only. Not medical advice. Both compounds are Schedule F in Canada.

Related reading

• Tadalafil pillar guide
• Tadalafil dosage guide
• Tadalafil side effects
• Tadalafil protocol
• Is tadalafil legal in Canada?